EMERGENT BIOSOLUTIONS INC. COMMON STOCK

Emergent BioSolutions and Pro Football Legend Emmitt Smith Raise Awareness of Ready to Rescue Campaign Timed to the Big Game in New Orleans

07 Feb 2025 08:06:54 By Nasdaq GlobeNewswire

Enrollment Starts in Africa CDC-Led MpOx Therapeutic Study (MOSA)

16 Jan 2025 08:00:03 By Nasdaq GlobeNewswire

Emergent BioSolutions Gains Exclusive Commercial Rights to KLOXXADO® (naloxone HCI) Nasal Spray from Hikma Pharmaceuticals

14 Jan 2025 07:30:34 By Nasdaq GlobeNewswire

Emergent BioSolutions Receives Contract Option Valued at Approximately $16.7 Million to Continue Development Collaboration with BARDA on Ebanga™ (ansuvimab-zykl) Treatment for Ebola

13 Jan 2025 09:27:39 By Nasdaq GlobeNewswire

Emergent BioSolutions to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 15, 2025

08 Jan 2025 07:45:00 By Nasdaq GlobeNewswire

Emergent BioSolutions Announces Exercise of $20 Million Option to Supply U.S. Department of Defense with BioThrax® (Anthrax Vaccine Adsorbed)

08 Jan 2025 07:30:00 By Nasdaq GlobeNewswire

Emergent BioSolutions Receives $50 Million Contract Option from BARDA to Procure Doses of CYFENDUS® (Anthrax Vaccine Adsorbed, Adjuvanted)

16 Dec 2024 08:00:00 By Nasdaq GlobeNewswire

Emergent BioSolutions Supports New Clinical Trial Evaluating the Safety and Efficacy of Brincidofovir in Treating Mpox Virus Across Africa

06 Nov 2024 16:49:03 By Nasdaq GlobeNewswire

Emergent BioSolutions Reports Third Quarter 2024 Financial Results

06 Nov 2024 16:05:01 By Nasdaq GlobeNewswire

Emergent BioSolutions Appoints Dr. Simon Lowry as Chief Medical Officer and Head of Research and Development

04 Nov 2024 07:30:00 By Nasdaq GlobeNewswire

Emergent BioSolutions to Release Third Quarter 2024 Financial Results and Conduct Conference Call on November 6, 2024

23 Oct 2024 07:30:55 By Nasdaq GlobeNewswire

Emergent BioSolutions Demonstrates Commitment to Increasing Access & Awareness of NARCAN® Nasal Spray to Help Combat the Opioid Epidemic

08 Oct 2024 17:32:28 By Nasdaq GlobeNewswire

Emergent BioSolutions Announces Closing of $100 Million Asset-Backed Loan Facility

02 Oct 2024 07:30:00 By Nasdaq GlobeNewswire

Emergent BioSolutions Announces the Execution of Contract Options Valued at $67.4 Million to Procure Additional TEMBEXA® (brincidofovir) to Support National Preparedness Efforts

26 Sep 2024 08:05:00 By Nasdaq GlobeNewswire

Emergent BioSolutions Confirms Approximately $400 million in Orders in 2024 & 2025 to Support Smallpox and Mpox Preparedness Efforts

25 Sep 2024 07:07:16 By Nasdaq GlobeNewswire

Emergent BioSolutions Announces Agreement to Settle Securities Class Action Litigation

13 Sep 2024 06:45:00 By Nasdaq GlobeNewswire

Emergent BioSolutions Awarded Research and Development Option valued at $41.9 Million for continued Advanced Development and Procurement of Ebanga™ Treatment for Ebola

12 Sep 2024 08:30:00 By Nasdaq GlobeNewswire

Emergent BioSolutions Successfully Refinances Debt & Further Strengthens Financial Profile

03 Sep 2024 07:08:45 By Nasdaq GlobeNewswire

Emergent BioSolutions Expands Ready to Rescue Initiative to Support Widespread Opioid Emergency Preparedness

30 Aug 2024 08:16:09 By Nasdaq GlobeNewswire

Emergent BioSolutions’ ACAM2000®, (Smallpox and Mpox (Vaccinia) Vaccine, Live) Receives U.S. FDA Approval for Mpox Indication; Public Health Mpox Outbreak Continues Across Africa & Other Regions

29 Aug 2024 18:53:02 By Nasdaq GlobeNewswire